Adequate performance status: 
Breast - Karnofsky score > 50; 
Ovarian, endometrial or cervical - Gynecologic Oncology Group (GOG) performance score ≤2 
If female and of childbearing potential, are willing to use adequate contraception (hormonal, barrier method, abstinence) prior to study entry and for the duration of study participation. 
Normal organ function within 14 days of study entry 
Diagnosis of one of the following malignancies: 
Metastatic breast cancer (BR) 
Metastatic ovarian cancer (OV) 
Metastatic endometrial cancer (EM) 
Metastatic cervical cancer (CX) 
Measurable metastatic disease (>1cm) in at least one site other than bone-only 
Progression on or failure to respond to at least one previous chemotherapy regimen for metastatic disease 
Progression on prior therapy with a hormonal agent if estrogen receptor or progesterone receptor positive, and/or with trastuzumab if HER2-neu positive. If patient has progressed through hormone or trastuzumab therapy only, must have received one chemotherapy regimen. 
Measurable metastatic disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 
Primary tumor must have been diagnosed histologically as either epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (not borderline or low malignant potential epithelial carcinoma). 
Subjects must have failed at least two previous chemotherapy regimens. Paclitaxel must have been a component of one or both regimens and cisplatin or carboplatin must have been a component of one or both regimens. 
Measurable metastatic disease 
Histologically proven recurrent or persistent endometrial cancer that is not amenable to curative treatment with surgery and/or radiation therapy AND has failed 2 previous treatment regimens 
Measurable metastatic disease 
Histologically proven recurrent or persistent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix that is not amenable to curative treatment with surgery and/or radiation therapy AND has failed 2 previous treatment regimens. 

NCT00319748_inc_T1
Measurement
Breast - Karnofsky score
NCT00319748_inc_T2
Value
> 50
NCT00319748_inc_T3
Measurement
Gynecologic Oncology Group (GOG) performance score
NCT00319748_inc_T4
Value
≤2
NCT00319748_inc_T5
Person
female
NCT00319748_inc_T6
Condition
childbearing potential
NCT00319748_inc_T7
Scope
female and of childbearing potential
NCT00319748_inc_T8
Observation
willing to
NCT00319748_inc_T9
Procedure
contraception
NCT00319748_inc_T10
Drug
hormonal
NCT00319748_inc_T11
Procedure
barrier method
NCT00319748_inc_T12
Procedure
abstinence
NCT00319748_inc_T13
Scope
hormonal, barrier method, abstinence
NCT00319748_inc_T14
Temporal
for the duration of study participation
NCT00319748_inc_T15
Temporal
prior to study entry
NCT00319748_inc_T16
Condition
Normal organ function
NCT00319748_inc_T17
Temporal
within 14 days of study entry
NCT00319748_inc_T18
Condition
Metastatic breast cancer
NCT00319748_inc_T19
Condition
Metastatic ovarian cancer
NCT00319748_inc_T20
Condition
Metastatic endometrial cancer
NCT00319748_inc_T21
Condition
Metastatic cervical cancer
NCT00319748_inc_T22
Condition
metastatic disease
NCT00319748_inc_T23
Qualifier
Measurable
NCT00319748_inc_T24
Value
>1cm
NCT00319748_inc_T25
Value
at least one
NCT00319748_inc_T26
Qualifier
site other than bone-only
NCT00319748_inc_T27
Observation
failure to respond
NCT00319748_inc_T28
Observation
Progression on
NCT00319748_inc_T30
Temporal
previous
NCT00319748_inc_T31
Procedure
chemotherapy regimen
NCT00319748_inc_T32
Condition
metastatic disease
NCT00319748_inc_T33
Scope
Progression on or failure to respond
NCT00319748_inc_T29
Observation
Progression on
NCT00319748_inc_T34
Temporal
prior
NCT00319748_inc_T35
Procedure
therapy with a hormonal agent
NCT00319748_inc_T36
Condition
estrogen receptor positive
NCT00319748_inc_T37
Condition
progesterone receptor positive
NCT00319748_inc_T38
Scope
estrogen receptor or progesterone receptor positive
NCT00319748_inc_T39
Condition
HER2-neu positive
NCT00319748_inc_T40
Procedure
therapy with trastuzumab
NCT00319748_inc_T41
Scope
prior therapy with a hormonal agent if estrogen receptor or progesterone receptor positive, and/or with trastuzumab if HER2-neu positive
NCT00319748_inc_T42
Observation
progressed through
NCT00319748_inc_T43
Procedure
hormone therapy
NCT00319748_inc_T44
Procedure
trastuzumab therapy
NCT00319748_inc_T45
Scope
progressed through hormone or trastuzumab therapy
NCT00319748_inc_T46
Procedure
chemotherapy regimen
NCT00319748_inc_T47
Measurement
Response Evaluation Criteria in Solid Tumors (RECIST)
NCT00319748_inc_T48
Condition
metastatic disease
NCT00319748_inc_T49
Condition
epithelial ovarian cancer
NCT00319748_inc_T50
Procedure
histologically
NCT00319748_inc_T51
Qualifier
Primary tumor
NCT00319748_inc_T52
Condition
fallopian tube cancer
NCT00319748_inc_T53
Condition
primary peritoneal cancer
NCT00319748_inc_T54
Qualifier
borderline
NCT00319748_inc_T55
Condition
epithelial carcinoma
NCT00319748_inc_T57
Scope
not borderline or low malignant potential epithelial carcinoma
NCT00319748_inc_T56
Scope
epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
NCT00319748_inc_T58
Multiplier
at least two
NCT00319748_inc_T59
Temporal
previous
NCT00319748_inc_T60
Procedure
chemotherapy regimens
NCT00319748_inc_T61
Observation
failed
NCT00319748_inc_T62
Drug
Paclitaxel
NCT00319748_inc_T63
Drug
cisplatin
NCT00319748_inc_T64
Drug
carboplatin
NCT00319748_inc_T65
Condition
metastatic disease
NCT00319748_inc_T66
Qualifier
Measurable
NCT00319748_inc_T67
Measurement
Histologically
NCT00319748_inc_T68
Value
proven
NCT00319748_inc_T71
Scope
recurrent or persistent endometrial cancer
NCT00319748_inc_T72
Qualifier
amenable to curative treatment
NCT00319748_inc_T73
Negation
not
NCT00319748_inc_T74
Procedure
surgery
NCT00319748_inc_T75
Procedure
radiation therapy
NCT00319748_inc_T76
Scope
surgery and/or radiation therapy
NCT00319748_inc_T77
Value
2
NCT00319748_inc_T78
Temporal
previous
NCT00319748_inc_T79
Procedure
treatment regimens
NCT00319748_inc_T80
Observation
failed
NCT00319748_inc_T81
Condition
metastatic disease
NCT00319748_inc_T82
Qualifier
Measurable
NCT00319748_inc_T83
Measurement
Histologically
NCT00319748_inc_T84
Value
proven
NCT00319748_inc_T85
Condition
squamous cell carcinoma
NCT00319748_inc_T86
Qualifier
persistent
NCT00319748_inc_T87
Qualifier
recurrent
NCT00319748_inc_T88
Scope
recurrent or persistent
NCT00319748_inc_T89
Condition
adenosquamous carcinoma
NCT00319748_inc_T90
Condition
adenocarcinoma of the cervix
NCT00319748_inc_T91
Qualifier
amenable to curative treatment
NCT00319748_inc_T92
Negation
not
NCT00319748_inc_T93
Procedure
surgery
NCT00319748_inc_T94
Procedure
radiation therapy
NCT00319748_inc_T95
Value
2
NCT00319748_inc_T96
Procedure
treatment regimens
NCT00319748_inc_T97
Temporal
previous
NCT00319748_inc_T69
Condition
endometrial cancer
NCT00319748_inc_T70
Qualifier
persistent
NCT00319748_inc_T98
Qualifier
recurrent
NCT00319748_inc_T99
Scope
recurrent or persistent
NCT00319748_inc_T100
Scope
squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix
NCT00319748_inc_T101
Negation
not
NCT00319748_inc_T102
Qualifier
low malignant potential
NCT00319748_inc_T103
Scope
borderline or low malignant potential
NCT00319748_inc_T104
Scope
Paclitaxel must have been a component of one or both regimens and cisplatin or carboplatin must have been a component of one or both regimens
NCT00319748_inc_T105
Reference_point
study entry
NCT00319748_inc_T106
Reference_point
study participation
NCT00319748_inc_T107
Reference_point
study entry
NCT00319748_inc_T108
Qualifier
Ovarian
NCT00319748_inc_T109
Qualifier
endometrial
NCT00319748_inc_T110
Qualifier
cervical
NCT00319748_inc_T111
Scope
Ovarian, endometrial or cervical
NCT00319748_inc_T112
Measurement
performance status
NCT00319748_inc_T113
Value
Adequate